Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan

Clinical Oncology

Volumn 22, Issue 6, 2010, Pages 438-447

  Chao, M ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Empirical radioiodine therapy; Negative diagnostic whole body scan; Rising thyroglobulin

Indexed keywords

(1 BUTYLAMINO 3 METHYLBUTYL)(1 PYRROLIDINYL) KETONE; FLUORODEOXYGLUCOSE F 18; IODINE 131; RADIOACTIVE IODINE; THYROGLOBULIN; THYROTROPIN; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ARTICLE; BONE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIATED THYROID CANCER; DRUG UPTAKE; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK PATIENT; HORMONAL REGULATION; HUMAN; LUNG; LYMPH NODE; MEDIASTINUM; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOACTIVITY; SURVIVAL RATE; THERAPY EFFECT; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID GLAND; WHOLE BODY SCINTISCANNING; BLOOD; CONTROLLED CLINICAL TRIAL (TOPIC); DIAGNOSTIC USE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCINTISCANNING; THYROID NEOPLASMS; WHOLE BODY COUNTING;

CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; IODINE RADIOISOTOPES; RADIOPHARMACEUTICALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THYROGLOBULIN; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; WHOLE-BODY COUNTING;

EID: 77954757481     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.05.005     Document Type: Article

References (56)

1. Ozata M., Suzuki S., Miyamoto T., Liu R.T., Fierro-Renoy F., DeGroot L.J. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994, 79:98-105.
2. Pacini F., Pinchera A. Serum and tissue thyroglobulin measurement: clinical applications in thyroid disease. Biochimie 1999, 81:463-467.
3. Chao M., Anren K., Jiawei X., Tiekun M. The possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scan. J Nucl Med 2005, 46:1473-1480.
4. Kloos R.T. Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer. J Clin Endocrinol Metab 2008, 93:1519-1525.
5. Chao M., Kuang A.R. Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases. Cochrane Database Syst Rev 2009, 1. CD006988.
6. Koh J.M., Kim E.S., Ryu J.S., et al. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study. Clin Endocrinol 2003, 58:421-427.
7. Pacini L., Agate R., Elisei M. Outcome of differentiated thyroid cancer with detectable serum Tg and negative 131I whole body scan: comparison of patients treated with high 131I activities versus untreated patients. J Clin Endocrinol Metab 2001, 86:4092-4097.
8. Tian R., Pan M., Kuang A. Evaluation of 131I therapy for differentiated thyroid carcinoma patients with elevated Tg and negative 131I whole body scan. Chin J Nucl Med 2003, 23:27-28.
9. De Keizer B., Koppeschaar H.P., Zelissen P.M., et al. Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin. Eur J Nucl Med 2001, 28:198-202.
10. Pineda J.D., Lee T., Ain K., et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995, 80:1488-1492.
11. Mazzaferri E.L., Kloos R.T. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001, 86:1447-1463.
12. Van Tol K.M., Jager P.L., De Vries E.G., et al. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. Eur J Endocrinol 2003, 148:589-596.
13. Pacini F., Lippi F., Formica N., et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987, 28:1888-1891.
14. Kabasakal L., Selcuk N.A., Shafipour H., et al. Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases. Eur J Nucl Med Mol Imag 2004, 31:1500-1504.
15. Fatourechi V., Hay I.D., Javedan H., et al. Lack of impact of radioiodine therapy in Tg-positive, diagnostic whole-body scan-negative patients with follicular cell derived thyroid cancer. J Clin Endocrinol Metab 2002, 87:1521-1526.
16. Pachucki J., Burmeister L.A. Evaluation and treatment of persistent thyroglobulinemia in patients with well-differentiated thyroid cancer. Eur J Endocrinol 1997, 137:254-261.
17. Ronga G., Fiorentino A., Paserio E., et al. Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma?. J Nucl Med 1990, 31:1766-1771.
18. Schaap J., Eustatia-Rutten C.F., Stokkel M., et al. Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma?. Clin Endocrinol (Oxf) 2002, 57:117-124.
19. Rosário P.W., Maia F.C., Barroso A.L., Purisch S. Arq Bras Endocrinol Metabol 2005, 49:246-252.
20. Saghari M., Gholamrezanezhad A., Mirpour S., et al. Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan. Nucl Med Commun 2006, 27:567-572.
21. Alzahrani A.S., Mohamed G., Al Shammary A., Aldasouqi S., Abdal Salam S., Shoukri M. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer. J Endocrinol Invest 2005, 28:540-546.
22. Gutiérrez Cardo A.L., Rodríguez Rodríguez J.R., Borrego Dorado I., Navarro González E., Tirado Hospital J.L., Vázquez Albertino R. Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course. Rev Esp Med Nucl 2007, 26:138-145.
23. Pace L., Klain M., Albanese C., et al. Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment. Eur J Nucl Med Mol Imag 2006, 33:179-183.
24. Zanotti-Fregonara P., Keller I., Rubello D., Calzada-Nocaudie M., Devaux J.Y., Hindié E. Thyrotropin variations may explain some positive radioiodine therapy scans in patients with negative diagnostic scans. J Endocrinol Invest 2009, 32:267-271.
25. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999, 354:1896-1900.
26. Ma Chao, Xie Jiawei, Kuang Anren Is blind 131I therapy justified for patients with negative Tg and positive 131I WBS?. J Nucl Med 2005, 46:1164-1170.
27. Mazzaferri E.L., Robbins R.J., Spencer C.A., et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003, 88:1433-1441.
28. Schlumberger M., Pacini F., Wiersinga W.M., et al. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol 2004, 151:539-548.
29. Schlumberger M.J. Papillary and follicular thyroid carcinoma. N Engl J Med 1998, 338:297-306.
30. Schlumberger M., Arcangioli O., Piekarski J.D., Tubiana M., Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 1988, 29:1790-1794.
31. Ozata M., Suzuki S., Miyamoto T., et al. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994, 79:98-105.
32. Cailleux A.F., Baudin E., Travagli J.P., Ricard M., Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?. J Clin Endocrinol Metab 2000, 85:175-178.
33. Pacini F., Capezzone M., Elisei R., Ceccarelli C., Taddei D., Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002, 87:1499-1501.
34. Robbins R.J., Chon J.T., Fleisher M., Larson S., Tuttle R.M. Is the serum thyroglobulin response to recombinant human TSH sufficient, by itself, to monitor for residual thyroid carcinoma?. J Clin Endocrinol Metab 2002, 87:3242-3247.
35. Haugen B.R., Pacini F., Reiners C., et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999, 84:3877-3885.
36. David A., Blotta A., Bondanelli M., et al. Serum thyroglobulin concentrations and (131)I whole body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. J Nucl Med 2001, 42:1470-1475.
37. Vitale G., Lupoli G.A., Ciccarelli A., et al. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. Clin Endocrinol (Oxf) 2002, 56:247-252.
38. Mazzaferri E.L., Kloos R.T. Is diagnostic iodine-131 scanning with recombinant human TSH (rhTSH) useful in the follow-up of differentiated thyroid cancer after thyroid ablation?. J Clin Endocrinol Metab 2002, 87:1490-1498.
39. Haugen B.R., Ridgway E.C., McLaughlin B.A., McDermott M.T. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 2002, 12:37-43.
40. Pacini F., Molinaro E., Lippi F., et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001, 86:5686-5690.
41. Wartofsky L. Management of low risk well differentiated thyroid cancer based only upon thyroglobulin measurement after recombinant human thyrotropin. The rhTSH-stimulated thyroglobulin Study Group. Thyroid 2002, 12:121-134.
42. Zoller M., Kohlfuerst S., Igerc I., et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?. Eur J Nucl Med Mol Imag 2007, 34:487-495.
43. Kim S.J., Lee T.H., Kim I.J., Kim Y.K. Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin. Eur J Radiol 2009, 70:17-24.
44. van Tol K.M., Jager P.L., Piers D.A., et al. Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 2002, 12:381-387.
45. Dong M.J., Liu Z.F., Zhao K., et al. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis. Nucl Med Commun 2009, 30:639-650.
46. Petrich T., Börner A.R., Otto D., Hofmann M., Knapp W.H. Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imag 2002, 29:641-647.
47. Chin B.B., Patel P., Cohade C., Ewertz M., Wahl R., Ladenson P. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004, 89:91-95.
48. Grunwald F., Kälicke T., Feine U., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999, 26:1547-1552.
49. Wang W., Macapinlac H., Larson S.M., et al. [18F]-2-fluoro-2-deoxyglucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999, 84:2291-2302.
50. Wong J.B., Kaplan M.M., Meyer K.B., Pauker S.G. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective. Endocrinol Metab Clin N Am 1990, 19:741-760.
51. Mazzaferri E.L. Management of differentiated thyriod carcinoma patients with negative whole-body radioiodine scans and elevated serum thyroglobulin levels. Practical management of thyroid cancer - A multidisciplinary approach 2006, Springer-Verlag, London, [Chapter 20]. E.L. Mazzaferri, C. Harmer, U.K. Mallick, P. Kendall-Taylor (Eds.).
52. Cooper D.S., Doherty G.M., Haughen B.R., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214.
53. 18F-fluorodeoxyglucose positron emission tomography scan. J Clin Endocrinol Metab 2010, 95:1169-1173.
54. Mallick U.K., Charalambous H. Current issues in the management of differentiated thyroid cancer. Nucl Med Commun 2004, 25:873-881.
55. Schlumberger M., Chougnet C., Brassard M., Leboulleux S., Baudin E. Molecular targeted therapies for patients with refractory thyroid cancer. Clin Oncol 2010, 22:448-455.
56. Mallick U.K. Thyroid cancer: evidence-based optimal management and the search for a cure. Clin Oncol 2010, 22. 394.